Neurocrine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

CEO

Kyle W. Gano

CEOKyle W. Gano

Employees

2,000

Employees2,000

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1992

Founded1992

Employees

2,000

Employees2,000

NBIX Key Statistics

Market cap

17.54B

Market cap17.54B

Price-Earnings ratio

26.79

Price-Earnings ratio26.79

Dividend yield

—

Dividend yield—

Average volume

1.35M

Average volume1.35M

High today

$180.00

High today$180.00

Low today

$171.14

Low today$171.14

Open price

$175.02

Open price$175.02

Volume

374.51K

Volume374.51K

52 Week high

$180.00

52 Week high$180.00

52 Week low

$122.14

52 Week low$122.14

Stock Snapshot

With a market cap of 17.54B, Neurocrine(NBIX) trades at $174.47. The stock has a price-to-earnings ratio of 26.79.

On 2026-07-06, Neurocrine(NBIX) stock moved within a range of $171.14 to $180.00. With shares now at $174.47, the stock is trading +1.9% above its intraday low and -3.1% below the session's peak.

Trading volume for Neurocrine(NBIX) stock has reached 374.51K, versus its average volume of 1.35M.

Over the past 52 weeks, Neurocrine(NBIX) stock has traded between a high of $180.00 and a low of $122.14.

NBIX News

Simply Wall St 3d

Vertiv Stock And 2 Low Risk Growth Picks For AI Infrastructure Investors

With services activity cooling in the UK, mixed signals across Europe, and growth pockets emerging in Asia, many investors are looking for a steadier core in th...

TipRanks 5d

Neurocrine initiates Phase 2 study of crinecerfont

Neurocrine (NBIX) Biosciences announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 mo...

Simply Wall St 6d

US High Growth Tech Stocks to Watch

The market remained flat over the last week, but over the past 12 months, it has risen by 20%, with earnings expected to grow by 19% per annum in the coming yea...

Analyst ratings

88%

of 32 ratings

Buy

87.5%

Hold

12.5%

Sell

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.